Ricky Ganim, MD
Interventional Cardiology · Humble, TXNPI 1295843019
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $102,084 of the $143,636 with a category attached, or 71.1%. Medtronic accounts for 71.7% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2019 at $108,071 and has fallen 92.0% since, to $8,654 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 925 payments — averaging $155.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$103K
- Angiodynamics, Inc.$14K
- Boston Scientific$8K
- Abbott$3K
- Novartis$2K
- Corindus Inc.$1K
- plus $11K from 54 others
Across 43 payments — averaging $18,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$461K
- Bard Peripheral Vascular, Inc.$142K
- GE HealthCare$125K
- Janssen Research & Development, LLC$62K
- AstraZeneca$18K
- Bayer$9K
What the payments were for
- Royalty or licence$102,08471%
- Consulting fees$3,7503%
- Travel & lodging$2,1992%
- Food & beverage$22,09515%
- Education$220%
- Other$13,4869%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$102,084
- Auryon Laser System 100-120 Vac$13,667
- GENERAL - THERAPIES$2,250
- CorPath GRX$1,283
- CROSSBOSS$1,247
- COREVALVE EVOLUT R$476
- Ensite Cardiac Mapping System$431
- Barostim Neo System$329
- GENERAL - STENTS$308
- Confirm Rx$292
- AVVIGO Guidance System$269
- Assure WCD$213
- Indigo$180
- AVEIR$175
- XIENCE ALPINE$174
- Supera peripheral stent system$169
- ADVISOR$163
- WATCHMAN Access System$159
- HawkOne$150
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$147
How this compares
$143,636 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $165,205 |
| EntrestoSacubitril/Valsartan | 94 | $118,122 |
| XareltoRivaroxaban | 95 | $107,514 |
| Repatha SureclickEvolocumab | 78 | $80,427 |
| BrilintaTicagrelor | 55 | $52,406 |
| Repatha SyringeEvolocumab | 31 | $33,631 |
| Praluent PenAlirocumab | 32 | $33,356 |
| FarxigaDapagliflozin Propanediol | 21 | $29,690 |
| JardianceEmpagliflozin | 16 | $12,360 |
| Rosuvastatin Calcium | 441 | $6,004 |
| ClopidogrelClopidogrel Bisulfate | 562 | $5,663 |
| Metoprolol Succinate | 384 | $5,348 |
| Ezetimibe | 209 | $5,141 |
| Icosapent Ethyl | 15 | $3,927 |
| Atorvastatin Calcium | 423 | $3,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $523 | $165,205151 claims |
| NovartisEntresto | $1,988 | $118,12294 claims |
| Johnson & JohnsonXarelto | $609 | $107,51495 claims |
| AstraZenecaBrilinta, Farxiga | $310 | $82,09676 claims |
| Boehringer IngelheimJardiance | $139 | $12,36016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Humble
- Khaled KhalafHumble$185K
- Madaiah RevanaHumble$92K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.